Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
View Patent ↗Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
1. A compound selected from the group consisting of:
5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquionoline,
3-methyl-5-(2-trifluoromethyl-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,
1,3-dimethyl-5-(3-trifluoromethylphenyl-1H-pyrazolo[4,3-c]-isoquinoline,
1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
1-benzyl-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
7methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,
7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H -pyrazolo[4,3-c]-isoquinoline,
7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
7-dimethylamino-3-methyl-5pyridin-2-yl-1H-pyrazolo]4,3-c]-isoquinoline,
6-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,
6-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
8-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
8-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline,
3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,
3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline, and
3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.
2. A pharmaceutical composition comprising a therapeutically effective content of at least one compound as claimed in claim 1 together with a pharmaceutically suitable carrier.
3. A method of treating a disease condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, asthma, comprising administering to a patient suffering from said disease condition a therapeutically effective amount of a compound according to claim 1 .
4. The method as claimed in claim 3 , wherein the disease condition is osteoarthritis.
5. The method as claimed in claim 3 , wherein the disease condition is rheumatoid arthritis.